Loading news...
Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the
Voya Investment Management LLC lessened its holdings in Surgery Partners, Inc. (NASDAQ: SGRY) by 86.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,842 shares of the company's stock after selling 88,405 shares during the period. Voya Investment Management
Sotera Health (NASDAQ: SHC - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Risk and Volatility Sotera Health has a
Caxton Associates LLP reduced its position in shares of Surgery Partners, Inc. (NASDAQ: SGRY) by 43.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 103,589 shares of the company's stock after selling 79,594 shares during the quarter. Caxton Associates LLP owned about 0.08% of Surgery
AYAL Capital Advisors Ltd purchased a new stake in Surgery Partners, Inc. (NASDAQ: SGRY) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 125,000 shares of the company's stock, valued at approximately $2,779,000. AYAL Capital Advisors Ltd owned
BRENTWOOD, Tenn., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), priced $425.0 million aggregate principal amount of its 7.250% senior unsecured notes due 2032 (the “Notes”) in a previously announced private offering exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The offering is expected to close on December 16, 2025, subject to certain customary closing conditions. The Notes will be guaranteed (the “Guarantees”) on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees the Issuer's obligations under its senior secured credit facilities. The notes will be issued as part of the same series as the $800.0 million of 7.250% senior notes due 2032 originally issued in April 2024.
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Surgery Partners, Inc. ("Surgery Partners" or the "Company") (NASDAQ: SGRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
BRENTWOOD, Tenn., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced today that Surgery Center Holdings, Inc., a wholly owned subsidiary of the Company (the “Issuer”), intends to offer, subject to market and other considerations, an additional $425.0 million aggregate principal amount of its 7.250% senior unsecured notes due 2032 (the “Notes”). The Notes will be guaranteed (the “Guarantees”) on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under its senior secured credit facilities. The notes will be issued as part of the same series as the Issuer's 7.250% senior notes due 2032 originally issued in April 2024.
Gabelli Funds LLC grew its position in Surgery Partners, Inc. (NASDAQ: SGRY) by 117.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 315,002 shares of the company's stock after purchasing an additional 170,057 shares during the quarter. Gabelli Funds LLC owned
Ardsley Advisory Partners LP boosted its position in Surgery Partners, Inc. (NASDAQ: SGRY) by 20.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 300,000 shares of the company's stock after acquiring an additional 50,000 shares during the period. Ardsley
Groupe la Francaise raised its position in Surgery Partners, Inc. (NASDAQ: SGRY) by 26.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 186,088 shares of the company's stock after purchasing an additional 39,089 shares during the period.
Elevance Health (NYSE: ELV - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership. Earnings and Valuation This table compares Elevance Health
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Surgery Partners, Inc. ("Surgery Partners" or the "Company") (NASDAQ: SGRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report) shares reached a new 52-week low during trading on Monday after Mizuho lowered their price target on the stock from $28.00 to $22.00. Mizuho currently has an outperform rating on the stock. Surgery Partners traded as low as $15.01 and last traded at $15.05, with a volume
Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock traders acquired 6,122 put options on the stock. This is an increase of 498% compared to the average volume of 1,024 put options. Wall Street Analyst Weigh In Several analysts recently issued reports on the
Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report)'s share price reached a new 52-week low on Monday after the company announced weaker than expected quarterly earnings. The stock traded as low as $18.37 and last traded at $18.0250, with a volume of 6889 shares changing hands. The stock had previously closed at $21.50. The company
It missed on the top line and whiffed significantly on analyst estimates in its third quarter. The company did manage to grow its revenue by almost 7% year over year.
Surgery Partners, Inc. ( SGRY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants David Doherty - Executive VP & CFO J. Evans - CEO & Director Conference Call Participants Brian Tanquilut - Jefferies LLC, Research Division Joanna Gajuk - BofA Securities, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Andrew Mok - Barclays Bank PLC, Research Division Sarah James - Cantor Fitzgerald & Co., Research Division Benjamin Mayo - Leerink Partners LLC, Research Division William Sutherland - The Benchmark Company, LLC, Research Division Ryan Langston - TD Cowen, Research Division Presentation Operator Greetings, and welcome to the Surgery Partners' Third Quarter 2025 Earnings Call.
Surgery Partners (SGRY) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.19 per share a year ago.
DOWNERS GROVE, Ill.--(BUSINESS WIRE)--Duly Health and Care, through its Chicagoland medical group, DuPage Medical Group, Ltd., has announced the acquisition of a minority ownership interest in Valley Ambulatory Surgery Center (Valley ASC) in partnership with Surgery Partners. This collaboration strengthens Duly's commitment to expanding access to high-quality, affordable outpatient surgical care across the Chicagoland area. Valley ASC, located in St. Charles, Illinois, is a respected, multispec.